Voyager Therapeutics, Inc.

www.voyagertherapeutics.com

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

news image

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More

BIO-K PLUS INTERNATIONAL IS EXPANDING ITS PORTFOLIO OF PROBIOTIC PRODUCTS AND IS LAUNCHING A NEW LINE OF FUNCTIONAL BEVERAGES INFUSED WITH PROBIOTICS

Bio-K | October 22, 2020

news image

Bio-K Plus International Inc. (Bio-K Plus), pioneer in the probiotic sector and leader in the biotech industry, is pleased to announce the launch of its new line of functional beverages, Essential. Focused on offering premium quality probiotics that make a real difference in people's lives around the world, the company is adding the Essential line to its existing Pro and Original lines. In keeping with this tradition of high quality, the Essential line fits perfectly into the active and mode...

Read More

MEDTECH

AVANTOR® WILL INCREASE GLOBAL PRODUCTION OF SINGLE-USE TECHNOLOGIES TO MEET THE BIOPHARMA DEMAND

Avantor | April 27, 2021

news image

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Read More

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

news image

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More
news image

INDUSTRIAL IMPACT

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More
news image

BIO-K PLUS INTERNATIONAL IS EXPANDING ITS PORTFOLIO OF PROBIOTIC PRODUCTS AND IS LAUNCHING A NEW LINE OF FUNCTIONAL BEVERAGES INFUSED WITH PROBIOTICS

Bio-K | October 22, 2020

Bio-K Plus International Inc. (Bio-K Plus), pioneer in the probiotic sector and leader in the biotech industry, is pleased to announce the launch of its new line of functional beverages, Essential. Focused on offering premium quality probiotics that make a real difference in people's lives around the world, the company is adding the Essential line to its existing Pro and Original lines. In keeping with this tradition of high quality, the Essential line fits perfectly into the active and mode...

Read More
news image

MEDTECH

AVANTOR® WILL INCREASE GLOBAL PRODUCTION OF SINGLE-USE TECHNOLOGIES TO MEET THE BIOPHARMA DEMAND

Avantor | April 27, 2021

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Read More
news image

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More